Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. - Wikidata - awgldk - TriplyDB

Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.

Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.

http://www.wikidata.org/entity/Q38126803

about

Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension A critical analysis of testosterone supplementation therapy and cardiovascular risk in elderly men.Tadalafil Integrates Nitric Oxide-Hydrogen Sulfide Signaling to Inhibit High Glucose-induced Matrix Protein Synthesis in Podocytes Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?Adulterated and Counterfeit Male Enhancement Nutraceuticals and Dietary Supplements Pose a Real Threat to the Management of Erectile Dysfunction: A Global Perspective.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Avanafil - a further step to tailoring patient needs and expectations.Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.Penile microvascular endothelial function in hypertensive patients: effects of acute type 5 phosphodiesterase inhibition.

P2860

Q26801345-C3DECA7D-AD53-4A0F-A4AD-94A4C0CF4BB7 Q33690473-BC710551-1A49-490F-8FF9-BEF33FB7CD87 Q35583071-C0265862-60BF-443C-AC09-38742C0329DE Q35840149-5B0BF477-3C1F-4CDA-AA7C-B6C0BE0BEC48 Q38429870-483D9500-14C0-49AF-82DE-1B64C58C29D5 Q38749357-BBC32495-FD75-461D-86E2-EA34CE051C5B Q38815890-0813FF54-8F04-4682-94D0-76AFB31DB70F Q38846047-05A9AE0F-2A38-4D04-8FBA-57B72D4F1DCB Q44338340-0B470AFA-D70D-4BB7-80F3-EC4009D886A1 Q49778102-E2007A24-6185-46D2-966A-E38B3FA90AF7

P2860

Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.

http://www.wikidata.org/entity/Q38126803

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Effectiveness and safety of ph ...... ular disease and hypertension.

@en

type

label

Effectiveness and safety of ph ...... ular disease and hypertension.

@en

prefLabel

Effectiveness and safety of ph ...... ular disease and hypertension.

@en

P1433

Q38126803-81D709FD-0D60-4EBA-BC91-56326EFB952C

P1476

Q38126803-3A0DCBF4-F864-4705-BF08-1396417CE0B6

P2093

Q38126803-63548146-EE66-4ABD-9F64-D998C6FA0CF4

P2860

Q38126803-12F74444-FD0C-4DF9-8095-06BF0F10A75D

Q38126803-17E725A0-9598-4662-AE1B-1AB4B7E75CD1

Q38126803-2440EDF1-5CF6-461C-A56A-0DE432FF44D8

Q38126803-2A0A8522-83F5-4B76-B6DC-923EA2866D83

Q38126803-2C53024C-A8EA-4DF4-8751-506D94348465

Q38126803-2D4436D5-1B33-42DC-AE24-3F478383D1BD

Q38126803-2F9570F9-D056-4B7F-BC92-FF0E30E56A85

Q38126803-2FB19571-BA9A-4B03-8671-A0259B571C19

Q38126803-356D1709-0255-4D96-B70D-6BF78B82987D

Q38126803-39DDFA19-6C64-4FDD-A681-7F394760EAD9

P2888

Q38126803-087FF893-F76F-48A2-A3D1-CC51C1E0C875

P304

Q38126803-87458A2C-9258-4DB0-AB5A-6717A40F3F92

P31

Q38126803-F00632A8-0C09-4195-902E-D6CE2DE870E9

P356

Q38126803-2830D93E-756A-425B-8F74-A6B1B0595F2D

P433

Q38126803-1B2D0B9F-5A40-4113-8AF4-FCB925E61AE4

P478

Q38126803-3A206DAD-91E4-480B-B3E6-FFD89ECDA7C5

P577

Q38126803-77B59066-4F36-4A2C-9477-82E8691D3655

P6179

Q38126803-954AD2C4-52BA-4C84-AD80-E076BB393E1A

P698

Q38126803-8CEBF3C4-8AD4-425A-8596-FFCF425DF507

P356

S11906-013-0377-9

P1433

Current Hypertension Reports

P1476

Effectiveness and safety of ph ...... ular disease and hypertension.

@en

P2093

Steven G Chrysant

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of human PDE7B, a cAMP-specific phosphodiesterase

Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase

Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase

Mitochondria as a therapeutic target in heart failure

Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A

Cardiovascular data on sildenafil citrate: introduction.

Sildenafil for male erectile dysfunction: a systematic review and meta-analysis.

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group.

Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.

Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.

P2888

s11906-013-0377-9

P304

475-483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11906-013-0377-9

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007780974

http://www.w3.org/2001/XMLSchema#string

P698

23917809

http://www.w3.org/2001/XMLSchema#string